Long-acting injectables are transforming schizophrenia treatment by ensuring medication adherence and reducing relapse rates.

If the FDA follows an advisory committee’s vote, it can potentially be a transformative step in the delivery of mental health ...

Disorganized schizophrenia involves severe cognitive, behavioral, and emotional symptoms. People with disorganized schizophrenia typically experience disorganized thinking, which means that they ...

A machine learning model trained on electronic health record (EHR) data predicted progression to schizophrenia or bipolar ...

FDA convened a joint meeting of its Drug Safety and Risk Management Advisory Committee and the Psychopharmacologic Drugs ...

A comprehensive analysis has identified novel enhancers associated with neuronal development and disease.

Among 196 doctors who prescribed clozapine, 64% said the positive aspects of the REMS certification process outweighed the ...

A new cohort study found that schizophrenia cases related to cannabis use disorder serious enough to warrant a person to seek emergency care increased afte ...

The following is a summary of “Management of Psychosis and Schizophrenia by Primary Care GPs: A Cross-Sectional Study in ...

Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...